Edition:
United Kingdom

Achieve Life Sciences Inc (ACHV.OQ)

ACHV.OQ on NASDAQ Stock Exchange Capital Market

1.85USD
19 Aug 2019
Change (% chg)

$0.04 (+2.21%)
Prev Close
$1.81
Open
$1.85
Day's High
$1.85
Day's Low
$1.85
Volume
1,134
Avg. Vol
44,089
52-wk High
$5.24
52-wk Low
$1.07

Latest Key Developments (Source: Significant Developments)

Achieve Reports Qtrly Loss Per Share $0.50
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2019 AND PROVIDES CYTISINICLINE CLINICAL DEVELOPMENT UPDATE.QTRLY LOSS PER SHARE $0.50.Q2 EARNINGS PER SHARE VIEW $-0.56 -- REFINITIV IBES DATA.  Full Article

Achieve Qtrly Loss Per Share $0.88
Wednesday, 15 May 2019 

May 15 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2019 AND PROVIDES CYTISINICLINE CLINICAL DEVELOPMENT UPDATE.ACHIEVE LIFE SCIENCES INC - QTRLY LOSS PER SHARE $0.88.ACHIEVE LIFE SCIENCES INC - AS OF MARCH 31, 2019, COMPANY'S CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND RESTRICTED CASH WERE $9.7 MILLION.  Full Article

Achieve Life Sciences - QTRLY Loss Per Share $0.71
Wednesday, 7 Nov 2018 

Achieve Life Sciences Inc ::ACHIEVE REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2018 AND PROVIDES CYTISINICLINE (CYTISINE) CLINICAL DEVELOPMENT UPDATE.ACHIEVE LIFE SCIENCES - QTRLY LOSS PER SHARE $0.71.  Full Article

Achieve Life Sciences Inc Qtrly Loss Per Share ‍$0.32​
Thursday, 1 Mar 2018 

March 1 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE LIFE SCIENCES INC QTRLY LOSS PER SHARE ‍$0.32​.  Full Article

Achieve Announces Prelim Data From Cytisine Phase I/II Clinical Study
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE ANNOUNCES PRELIMINARY DATA FROM CYTISINE PHASE I/II MULTI-DOSE, PHARMACOKINETIC AND PHARMACODYNAMICS (PK/PD) CLINICAL STUDY.ACHIEVE LIFE SCIENCES INC - CYTISINE WAS WELL-TOLERATED AND REPORTED ADVERSE EVENTS WERE MOSTLY MILD AND SHORT-LIVED IN STUDY.ACHIEVE LIFE SCIENCES - SUBJECTS WHO DID NOT ACHIEVE ABSTINENCE HAD "SIGNIFICANT REDUCTION" IN NUMBER OF DAILY CIGARETTES SMOKED BY END OF TREATMENT.ACHIEVE LIFE SCIENCES INC - NO ADVERSE EVENTS WERE SEVERE, SERIOUS, OR LED TO WITHDRAWAL FROM STUDY.ACHIEVE LIFE SCIENCES INC - EXPECTS TO INITIATE CYTISINE PHASE 3 DEVELOPMENT PROGRAM IN MID-2018 REQUIRED FOR FDA APPROVAL OF CYTISINE IN U.S..  Full Article

Achieve qtrly loss per share $0.90‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Achieve Life Sciences Inc ::Achieve reports financial results for third quarter 2017.Achieve Life Sciences Inc qtrly loss per share $0.90‍​.  Full Article

Achieve Life Sciences entered into exclusive supply agreement with Sopharma AD
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Sopharma Ad <3JR.BB>:Achieve Life Sciences -‍ co entered into exclusive supply agreement with Sopharma AD for manufacture of Cytisine API and finished tablets​.Achieve Life Sciences Inc - ‍exclusive license agreement provides supply of Cytisine to co for up to 20 years​.Achieve Life Sciences Inc - ‍sopharma agrees to produce CGMP-grade Cytisine for achieve's use in development and commercialization of Cytisine​.  Full Article

Achieve announces share purchase agreement with Lincoln Park Capital Fund
Thursday, 14 Sep 2017 

Sept 14 (Reuters) - Achieve Life Sciences Inc :Achieve announces share purchase agreement with Lincoln Park Capital Fund LLC.Achieve Life Sciences - ‍Entered share purchase agreement with Lincoln Park Capital Fund pursuant to which achieve may sell up to $11.0 million of shares.Achieve Life Sciences - Intends to use net proceeds it receives from offering to advance clinical development of Cytisine, among others​.  Full Article